Ipamorelin

Ipamorelin is a pentapeptide (5 amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that binds to the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor, located on somatotroph cells in the anterior pituitary gland. When activated, GHS-R1a triggers a calcium-dependent signaling cascade that causes the somatotrophs to release stored growth hormone in a burst (pulse). This mimics the body's natural pulsatile GH secretion pattern.

What makes ipamorelin unique among GHRPs is its remarkable selectivity for GH release. The original Raun et al. study demonstrated that ipamorelin, even at doses producing maximal GH release, did not significantly elevate plasma ACTH, cortisol, prolactin, FSH, or LH. In contrast, GHRP-6 at equivalent GH-releasing doses significantly increased ACTH and cortisol (stress hormones), while GHRP-2 elevated both cortisol and prolactin. This selectivity means ipamorelin can be used at effective doses without the hormonal side effects that limit other GHRPs.

Ipamorelin is most effective when combined with a GHRH analog (CJC-1295 without DAC / Mod GRF 1-29). This combination leverages the synergistic interaction between two different receptor systems: GHRH receptors on somatotrophs amplify the size of each GH pulse (set by GHRH), while GHS-R1a activation triggers the actual pulse release (set by ipamorelin). Together, they produce GH peaks 3-4x above baseline — significantly more than either alone.

The pharmacokinetics of ipamorelin are characterized by a short half-life of approximately 2 hours. Peak GH levels occur 20-40 minutes after subcutaneous injection. This short duration is actually desirable because it produces discrete GH pulses rather than sustained GH elevation (which is less physiological and can cause receptor desensitization). The body's natural GH secretion occurs in pulses, primarily during deep sleep, and ipamorelin administration mimics this pattern.

Ipamorelin's clinical evidence includes Phase 1/2 trials demonstrating dose-dependent GH release in healthy adults. The pivotal Raun et al. (1998) study tested intravenous doses of 0.01, 0.03, 0.06, 0.1, and 1.0 mcg/kg and showed that GH release peaked at 0.1 mcg/kg with no further increase at higher doses (indicating receptor saturation). At all doses, cortisol, ACTH, prolactin, FSH, LH, and TSH remained at baseline levels.

A Phase 2 clinical trial studied ipamorelin for postoperative ileus (delayed gut motility after abdominal surgery) under the trade name MP-214. While this trial explored a non-traditional application, it provided human safety data at doses up to 30 mcg/kg IV — far higher than typical research use — with no significant adverse events. The ileus trial did not meet its primary endpoint, but the safety data was reassuring.

In anti-aging medicine, ipamorelin (often combined with CJC-1295) is one of the most commonly prescribed peptide protocols by longevity-focused physicians. Real-world outcomes from clinical practice (observational, not RCT) report improvements in body composition (reduced fat mass, maintained or increased lean mass), sleep quality, skin elasticity, and recovery from exercise. These outcomes align with the known effects of optimized GH/IGF-1 levels but have not been validated in large randomized controlled trials.

IGF-1 levels typically increase 30-80% above baseline with consistent ipamorelin + CJC-1295 use over 3-6 months, based on clinical lab data from anti-aging physicians. This places most patients within the upper-normal physiological range rather than supraphysiological levels — an important distinction from exogenous GH administration which can produce IGF-1 levels far above normal.

Standard research dosing: 100-300mcg per injection, administered subcutaneously. When stacked with CJC-1295 (Mod GRF 1-29), the most common protocol is 100mcg ipamorelin + 100mcg CJC-1295 combined in the same syringe. This combination is injected 1-3 times daily, with the most important dose being before bed (to amplify the natural nocturnal GH surge that occurs during deep sleep).

Timing matters significantly for ipamorelin. GH release is blunted by elevated blood glucose and insulin. Ipamorelin should be injected at least 2 hours after the last meal and at least 30 minutes before eating. The three most common injection times: (1) first thing in the morning, fasted; (2) post-workout (after glycogen depletion); (3) before bed (most important — amplifies sleep-phase GH pulse). Before-bed dosing alone produces meaningful results for most researchers.

Reconstitution: a 5mg vial with 2.5mL BAC water yields 2000mcg/mL. For a 100mcg dose: draw 5 units on a U-100 syringe. For 200mcg: 10 units. For 300mcg: 15 units. The lower concentration (compared to 1mL reconstitution) makes smaller doses easier to measure accurately.

Cycling: Most protocols use 5 days on, 2 days off (weekdays only) to prevent theoretical receptor desensitization. Longer cycles of 3-6 months with 1-month breaks are also common. Some anti-aging physicians prescribe continuous use for 6-12 months without breaks, though the 5/2 pattern is more conservative. Ipamorelin does not suppress the pituitary's natural GH production at physiological doses, so cycling is a precautionary rather than mandatory measure.

Ipamorelin has the cleanest side effect profile of any GHRP studied in humans. The defining characteristic — confirmed in the original Phase 1 study and consistent across all subsequent data — is the absence of cortisol, prolactin, ACTH, or other hormonal elevation at GH-releasing doses. This eliminates the main concerns associated with other GH secretagogues.

Common mild effects include: water retention (transient, dose-dependent, typically resolves within 2-3 weeks as the body adapts), tingling or numbness in extremities (mild carpal tunnel-like symptoms from elevated IGF-1, dose-dependent and reversible), fatigue/drowsiness when dosed before bed (desirable for sleep-phase dosing), and mild flushing immediately after injection (transient, lasting minutes).

Ipamorelin does not significantly stimulate appetite (unlike GHRP-6, which strongly activates ghrelin-mediated hunger). This makes it more suitable for body recomposition protocols where appetite suppression is preferred. It does not affect thyroid function, testosterone production, or any reproductive hormones.

Long-term safety data is limited to clinical practice observations rather than long-duration RCTs. The theoretical concern with any GH-elevating therapy is cancer risk — GH and IGF-1 are growth factors, and sustained elevation could theoretically promote tumor growth. However, ipamorelin produces physiological (not supraphysiological) GH/IGF-1 elevation, and no association with cancer has been reported in published literature. Patients with active cancer or history of cancer should discuss GH-elevating therapies with their oncologist.